French biotechnology company at Bordeaux, founded in 2013 out of Inserm and University of Bordeaux research on the endocannabinoid system and listed on Euronext. Develops signalling specific inhibitors of the CB1 receptor, molecules that damp down overactive signalling without blocking the receptor outright, with candidates in clinical trials for cannabis use disorder and other brain conditions.
Aucun commentaire disponible.
Laissez votre note & commentaire